Drug Discovery and Development
Technology in Transition

Edited by

RG Hill BPharm PhD DSc (Hon) FMedSc
President Emeritus, British Pharmacological Society; Visiting Professor of Pharmacology, Department of Medicine, Imperial College, London; Formerly, Executive Director and Head, Licensing and External Research, Europe, MSD/Merck Research Laboratories

HP Rang MB BS MA DPhil FMedSci FRS
President-Elect British Pharmacological Society, Emeritus Professor of Pharmacology, University College, London; Formerly Director, Novartis Institute for Medical Sciences, London

Foreword by

Patrick Vallance DSc MB BS FRCP FMedSci
President, Pharmaceuticals Research and Development, GlaxoSmithKline, Brentford, UK
### Section 1: Introduction and background

1. The development of the pharmaceutical industry ........................................ 3  
   \textit{H P Rang}

2. The nature of disease and the purpose of therapy ..................................... 19  
   \textit{H P Rang, R G Hill}

3. Therapeutic modalities .................................................................................. 33  
   \textit{H P Rang, H LeVine, R G Hill}

### Section 2: Drug discovery

4. The drug discovery process: general principles and some case histories ........ 43  
   \textit{H P Rang, R G Hill}

5. Choosing the project .................................................................................... 57  
   \textit{H P Rang, R G Hill}

6. Choosing the target ...................................................................................... 63  
   \textit{H P Rang, R G Hill}

7. The role of information, bioinformatics and genomics ................................. 77  
   \textit{B Robson, R McBurney}

8. High-throughput screening .......................................................................... 95  
   \textit{D Cronk}

9. The role of medicinal chemistry in the drug discovery process .................. 119  
   \textit{P Beswick, A Naylor}

10. Metabolism and pharmacokinetic optimization strategies in drug discovery ................................................................. 135  
    \textit{P Ballard, P Brassil, K H Bui, H Dolgos, C Petersson, A Tunek, P J H Webbourn}

11. Pharmacology: its role in drug discovery .................................................. 157  
    \textit{H P Rang}

12. Biopharmaceuticals ..................................................................................... 171  
    \textit{H LeVine}

13. Scaffolds: small globular proteins as antibody substitutes .......................... 189  
    \textit{D Grabulovski, J Bertschinger}

### Section 3: Drug development

14. Drug development: introduction ................................................................ 203  
    \textit{H P Rang, R G Hill}

15. Assessing drug safety .................................................................................. 211  
    \textit{H P Rang, R G Hill}

16. Pharmaceutical development ..................................................................... 227  
    \textit{T Lundqvist, S Bredenberg}

17. Clinical development: present and future ................................................ 239  
    \textit{C Keywood}

18. Clinical imaging in drug development ....................................................... 259  
    \textit{P M Matthews}
Contents

19. Intellectual property in drug discovery and development ........................................ 275
   P Grubb

20. Regulatory affairs ................................................. 285
    I Hägglöf, Å Holmgren

21. The role of pharmaceutical marketing .......................................................... 303
    V M Lawton

Section 4: Facts and figures

22. Drug discovery and development: facts and figures ........................................ 321
    H P Rang, R G Hill

Index .................................................................................................................. 335